CD133-CXCR4+ovarian cancer cells expressed less sensitive to cisplatin and higher level of ABCG2 transporters than CD133-CXCR4- ovarian cancer cells displaying a drug resistance phenotype [35]. This evidence concerns the gene PROM1 and ovarian carcinoma.